What is JDS-HF3.0 studying for menopause symptoms?

JDS-HF3.0 is being studied to see if it can improve quality of life by reducing common menopause symptoms like joint discomfort, hot flashes, and night sweats. Researchers want to find out if taking this supplement daily for 12 weeks helps lessen these symptoms. The study is led by Bonafide Health and involves women aged 50 to 70.

Who may be eligible for this menopause clinical trial?

Women aged 50 to 70 who are postmenopausal with natural menopause may be eligible. Participants should have moderate to severe menopause-related joint discomfort and experience at least 4 hot flashes daily. They must be in good general health and have reliable internet access. Please review eligibility criteria for more details.

Is there any cost to participate in this menopause clinical trial?

Study-related care, including the supplement and all trial visits, is provided at no cost. Personal travel expenses may vary and are not guaranteed to be covered. Participants should be prepared for any costs related to their own travel or device use.

Actively Recruiting

Phase Not Applicable

Age: 50Years - 70Years

FEMALE

Healthy Volunteers

ID07238478

Study to Test JDS-HF3.0 Supplement for Improving Quality of Life and Reducing Menopause Symptoms in Women Aged 50 to 70

Led by Bonafide Health · Updated on 2025-11-20

250

Participants Needed

Research Sites

13 weeks

Total Duration

AI-Summary

What this Trial Is About

Researchers are studying whether taking the supplement JDS-HF3.0 can improve quality of life and lessen common menopause symptoms like joint discomfort, hot flashes, and night sweats in women aged 50 to 70. This study aims to find out if daily use of this product for 12 weeks reduces how often and how severe these menopausal symptoms are. About 250 postmenopausal women across the U.S. will take part in this randomized, placebo-controlled trial. Participants will be randomly assigned to one of two groups one group takes the active JDS-HF3.0 supplement, and the other takes a nonactive placebo. Each participant will take two tablets every morning for about 12 weeks. The entire study lasts roughly 14 weeks, including the time spent collecting initial baseline information. All parts of the study are conducted virtually, with no in-person visits required. Throughout the study, participants will complete daily diaries and weekly or monthly questionnaires about their menopause symptoms and overall well-being. There will be five virtual check-ins including screening, baseline, two during the study, and a final visit. Researchers will monitor changes in menopause-related quality of life from enrollment to the end of the study at 12 weeks. This includes tracking symptom severity and frequency, with safety and adherence closely observed during the trial.

CONDITIONS

Brief Title

JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women

How This Trial Compares With Other Options

This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.

Factors	JDS-HF3.0 (Active Supplement)	Placebo Supplement	NSAID Therapy (Standard of Care)
What it is	An investigational dietary supplement formulated to support menopause-related quality of life and target joint discomfort, hot flashes, and vasomotor symptoms.	A matching placebo supplement used as a control for comparison with the active supplement arm.	NSAIDs are established anti-inflammatory pain-relief medicines commonly used to treat joint discomfort and moderate musculoskeletal pain in postmenopausal women.
Role in the trial	Participants are randomly assigned to receive the active supplement and are monitored for changes in menopause-related symptoms and joint discomfort.	Participants take the placebo supplement as a control group to allow comparison with the active supplement group.	Used in routine clinical practice for joint pain and discomfort management during menopause, not part of the trial arms.
Primary use	Intended to address joint discomfort, vasomotor symptoms like hot flashes, and overall menopause-related quality of life.	Serves as a comparator to assess the efficacy of the supplement against no active intervention.	Provides pain relief and reduces inflammation in moderate to severe joint discomfort, including menopause-related arthralgia.
How it is given/performed	Taken orally as a daily supplement over a 12-week study period.	Taken orally in identical manner to the active supplement.	Usually prescribed as oral tablets or capsules, using standard dose schedules recommended for joint pain management.
Evidence status	Efficacy and safety are currently being evaluated in this randomized clinical trial; no published outcome evidence available yet.	Used as a reference to measure changes and symptom response relative to the active supplement.	NSAIDs have extensive published efficacy in joint pain and menopause-related arthralgia, improving pain and function in multiple guideline-reviewed studies.
Important limitations	Safety and symptom benefit have not yet been established, and results remain to be published. Limited evidence exists on supplement effectiveness for menopause-related joint discomfort.	Placebo arm does not offer active symptom relief but is necessary for evaluating true supplement effects versus expectation.	NSAIDs are effective for joint pain, but may pose gastrointestinal, cardiovascular, and renal risks, especially in older women. Individual risk assessment is necessary before use.

Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.

Who Can Participate

Age: 50Years - 70Years

FEMALE

Healthy Volunteers

Eligibility Criteria

You may qualify if you...

Healthy biological females aged 50 to 70 years inclusive
Body mass index (BMI) between 18.5 and 34.9 kg/m2 inclusive
Postmenopausal for at least 12 months due to natural menopause, with menopausal symptoms for past 6 months
Moderate to severe menopause-related joint discomfort rated between 5 and 9 on a 0-10 scale
Experience at least 4 hot flashes on average per day
Good general health with no active or uncontrolled diseases
Able to consume the study product
Agree to avoid certain treatments during defined timeframes
Have reliable, stable access to Wi-Fi and a smartphone or device
Willing and able to consent, understand questionnaires, and complete all study procedures

You will not qualify if you...

Lactating, pregnant, or planning pregnancy during the study
Currently participating in another clinical trial
Using treatments for menopausal symptoms or joint health that may interfere
Known allergy or intolerance to the study product or its ingredients
Use of glucosamine or chondroitin in past 3 months
Received COVID-19 vaccine within 2 weeks before screening or during study
Current COVID-19 infection or long COVID condition
History of heart, kidney, liver disease, or active systemic infections
Cancer history within 2 years except localized skin cancer without spread
Any significant disease that may increase risk or affect participation
Gastrointestinal, hepatic, or renal diseases affecting drug absorption or digestion
Difficulty swallowing or digestive tract abnormalities
Major surgery within 3 months before screening or planned during study
History of alcohol or substance abuse in past 5 years
Inflammatory rheumatic or autoimmune diseases
Chronic use of curcumin or curcuminoids unless willing to wash out for 3 months
Use of chronic pain medications or specific analgesics for joint discomfort unless willing to wash out for 2 weeks
Severe joint or bone deformities
Diagnosed bone fractures
Candidate for surgical joint replacement

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (virtual)

Treatment

Duration - About 12 weeks

Participants take two tablets each morning of either the active supplement or placebo and complete symptom diaries and questionnaires to report on menopausal symptoms and quality of life.

4 virtual check-ins including baseline, two during treatment, and a final visit